MedTrace Logo

Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy

NCT04696328 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-04-20

No results posted yet for this study

Summary

Targeting patients with severe ischemic cardiomyopathy, the purpose of this study is as follows: to confirm short-term efficacy by observing changes and transitions in cardiac function and clinical symptoms compared with each patient's baseline (before and after comparison) by human iPS cell-derived cardiomyocyte sheet transplantation, and to evaluate the safety and tolerability including the combined use of immunosuppressants.

Conditions

  • Myocardial Ischemia

Interventions

BIOLOGICAL

Human (allogeneic) iPS cell derived-cardiomyocyte sheet

Transplantation

Sponsors & Collaborators

  • Cuorips Inc.

    collaborator UNKNOWN

  • Osaka University

    lead OTHER

Principal Investigators

  • Yoshiki Sawa, Ph.D · Osaka University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2022-05-30
Completion
2023-05-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04696328 on ClinicalTrials.gov